I just saw this today, could be a good thing! Vidofludimus calcium (IMU-838) is a small molecule investigational drug in development as an oral next generation treatment option for patients with MS, and other chronic inflammatory and autoimmune diseases.

Vidofludimus Calcium is targeted to address multiple drivers of nuerodgeneration in MS patients. It is being tested in several ongoing MS trials, including the twin phase 3 ENSURE trials in relapsing multiple sclerosis and the supportive phase 2 CALIPER trial in progressive multiple sclerosis. If approved, Vidofludimus calcium, with combined anti-inflammatory, anti-viral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the comp;ex pathophysiology of MS.